Stockscreener 앱 받기
2.06
8.85%
-0.20
시간 외 거래:
2.06
전일 마감가:
$2.26
열려 있는:
$2.26
하루 거래량:
129.31K
Relative Volume:
0.83
시가총액:
$72.28M
수익:
-
순이익/손실:
$-17.78M
주가수익비율:
-3.7509
EPS:
-0.5492
순현금흐름:
$-10.52M
1주 성능:
+3.78%
1개월 성능:
-14.52%
6개월 성능:
-58.22%
1년 성능:
+0.00%
1일 변동 폭
$2.05
$2.28
1주일 범위
$1.97
$2.335
52주 변동 폭
$1.0779
$55.00
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
FBLG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
2.06 | 72.28M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
Geode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Barclays PLC Buys 31,331 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Bought by State Street Corp - Defense World
FibroBiologics Secures Second Tranche of $5 Million Financing - Defense World
FibroBiologics Announces $25 Million Financing - citybiz
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Secures Second $5M Tranche of $25M Equity Purchase Agreement with Yorkville Advisors - StockTitan
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - The Manila Times
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - GlobeNewswire Inc.
FibroBiologics (NASDAQ:FBLG) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - MarketBeat
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
FibroBiologics announces $25 million financing - MSN
FibroBiologics, Inc. announced that it expects to receive $15 million in funding from Yorkville Advisors Global LP - Marketscreener.com
FibroBiologics secures $25 million equity deal with Yorkville - Investing.com
FibroBiologics Secures $25M Equity Agreement for Trials - TipRanks
FibroBiologics Secures $25M Financing Deal to Advance Clinical Trials in Diabetic Foot Ulcers, Psoriasis - StockTitan
FibroBiologics finalizes agreement and terminates warrant By Investing.com - Investing.com Canada
FibroBiologics finalizes agreement and terminates warrant - Investing.com
Ionq Inc (IONQ-N) QuotePress Release - The Globe and Mail
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Update - MarketBeat
Rodman & Renshaw Initiates Coverage of FibroBiologics (FBLG) with Buy Recommendation - MSN
FibroBiologics (NASDAQ:FBLG) Coverage Initiated at Rodman & Renshaw - MarketBeat
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Up 7.2% in November - MarketBeat
FBLG: On Target to Initiate Phase 1/2 Trial in 2025… - MSN
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewswire
FibroBiologics seeks patent for spleen disorder treatment By Investing.com - Investing.com Australia
FibroBiologics seeks patent for spleen disorder treatment - Investing.com India
FibroBiologics Files Patent for Breakthrough Splenomegaly Cell Therapy Treatment | FBLG Stock News - StockTitan
HC Wainwright Expects Stronger Earnings for FibroBiologics - MarketBeat
HC Wainwright Reaffirms Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Fibrobiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction in Cell-Based Therapeutics - Marketscreener.com
FibroBiologics files patent for reducing cell therapy risks - Investing.com
FibroBiologics seeks patent for clot-prevention method - Investing.com
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewswire
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with ... - The Bakersfield Californian
FibroBiologics Files Patent for Breakthrough Cell Therapy Blood Clotting Prevention | FBLG Stock News - StockTitan
Is FibroBiologics (NASDAQ:FBLG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
FibroBiologics files patent for reducing cell therapy risks By Investing.com - Investing.com Nigeria
FibroBiologics' (FBLG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Reports Wider Q3 Loss, Advances Clinical Pipeline Amid R&D Push | FBLG Stock News - StockTitan
FibroBiologics Inc. (FBLG) Quarterly 10-Q Report - Quartz
FBLGFibroBiologics, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on FibroBiologics (NASDAQ:FBLG) - Defense World
HC Wainwright Forecasts FibroBiologics Q3 Earnings - MarketBeat
H.C. Wainwright sets stock target on FibroBiologics shares, cites portfolio By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ:FBLG) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
FibroBiologics names interim CFO as Mark Andersen steps down By Investing.com - Investing.com Australia
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday - Benzinga
FibroBiologics CFO Andersen Resigns - MarketWatch
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
0.05%
자본화:
|
볼륨(24시간):